MorphoSys AG (NASDAQ:MOR) Given Consensus Rating of “Hold” by Brokerages

MorphoSys AG (NASDAQ:MORGet Free Report) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $14.00.

Several research analysts recently weighed in on MOR shares. JPMorgan Chase & Co. raised MorphoSys from an “underweight” rating to an “overweight” rating and increased their target price for the stock from $3.30 to $10.00 in a research report on Friday, June 16th. UBS Group initiated coverage on MorphoSys in a research note on Wednesday, May 31st. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft upgraded MorphoSys from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Wells Fargo & Company started coverage on MorphoSys in a report on Friday, June 16th. They set an “overweight” rating and a $17.00 price target on the stock.

Get Our Latest Stock Report on MOR

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. UBS Group AG boosted its holdings in MorphoSys by 122.7% in the third quarter. UBS Group AG now owns 5,141 shares of the company’s stock worth $26,000 after purchasing an additional 2,832 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of MorphoSys during the second quarter valued at about $53,000. BNP Paribas Arbitrage SNC raised its position in shares of MorphoSys by 9,680.0% during the second quarter. BNP Paribas Arbitrage SNC now owns 9,780 shares of the company’s stock valued at $73,000 after buying an additional 9,680 shares during the last quarter. Two Sigma Securities LLC acquired a new position in shares of MorphoSys during the first quarter valued at about $86,000. Finally, Citadel Advisors LLC acquired a new position in MorphoSys in the third quarter worth about $101,000.

MorphoSys Stock Performance

Shares of NASDAQ:MOR opened at $7.54 on Friday. The business’s fifty day moving average price is $7.71 and its two-hundred day moving average price is $6.23. The company has a current ratio of 3.57, a quick ratio of 3.27 and a debt-to-equity ratio of 7.56. MorphoSys has a one year low of $3.17 and a one year high of $8.67.

MorphoSys (NASDAQ:MORGet Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.59) earnings per share (EPS) for the quarter. MorphoSys had a return on equity of 154.85% and a net margin of 27.67%. The business had revenue of $57.91 million for the quarter. Sell-side analysts forecast that MorphoSys will post -1.94 EPS for the current fiscal year.

About MorphoSys

(Get Free Report

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Featured Articles

Analyst Recommendations for MorphoSys (NASDAQ:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with's FREE daily email newsletter.